Published in
American Association for the Advancement of Science, Science Translational Medicine, 484(11), 2019
DOI: 10.1126/scitranslmed.aar5012
Links
Tools
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Journal article published in 2019 by
Marie-Eve Beaulieu 
,
Toni Jauset,
Daniel Massó-Vallés ,
Sandra Martínez-Martín ,
Peter Rahl,
Loïka Maltais ,
Mariano F. Zacarias-Fluck ,
Sílvia Casacuberta-Serra ,
Erika Serrano del Pozo ,
Christopher Fiore ,
Laia Foradada,
Virginia Castillo Cano ,
Meritxell Sánchez-Hervás,
Matthew Guenther,
Eduardo Romero Sanz
and other authors.
,
Toni Jauset,
Daniel Massó-Vallés ,
Sandra Martínez-Martín ,
Peter Rahl,
Loïka Maltais ,
Mariano F. Zacarias-Fluck ,
Sílvia Casacuberta-Serra ,
Erika Serrano del Pozo ,
Christopher Fiore ,
Laia Foradada,
Virginia Castillo Cano ,
Meritxell Sánchez-Hervás,
Matthew Guenther,
Eduardo Romero Sanz
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
We demonstrate the pharmacologic potential of the purified cell-penetrating Omomyc mini-protein to directly inhibit MYC function in vitro and in vivo.